LATEST
Arab States as Targets: The Warning Over Israel’s Emerging Doctrine of Permanent WarGaza’s Genocide: The Farce of Letting Israel Mark Its Own Homework While UN Investigators Are Kept OutKUKUI Appoints Heather Myers CEO to Lead Next Era of AI-Powered InnovationNew Video Game Lets Players Control a Human Through AI — One Wrong Instruction Can Kill ThemFrom ‘God Mode’ to Normal Life: Some IDF Soldiers Return From Gaza Depressed by Lost PowerLudera Introduces Priority MiCA Compliance Integration Program for Leading Crypto ExchangesComrod Acquires TransOpto to Expand Tactical Communications CapabilitiesAs AI Floods Financial Advice, a 60-Year Columbus Firm Doubles Down on What Cannot Be Automated: JudgmentBriton Pictured Beside Burning Gaza School Faces Call for War Crimes InquiryMercury Launches Next-Generation Retail Automation Platform to Expand 24/7 Retail Access Across Airports, Hospitality and High-Demand LocationsArab States as Targets: The Warning Over Israel’s Emerging Doctrine of Permanent WarGaza’s Genocide: The Farce of Letting Israel Mark Its Own Homework While UN Investigators Are Kept OutKUKUI Appoints Heather Myers CEO to Lead Next Era of AI-Powered InnovationNew Video Game Lets Players Control a Human Through AI — One Wrong Instruction Can Kill ThemFrom ‘God Mode’ to Normal Life: Some IDF Soldiers Return From Gaza Depressed by Lost PowerLudera Introduces Priority MiCA Compliance Integration Program for Leading Crypto ExchangesComrod Acquires TransOpto to Expand Tactical Communications CapabilitiesAs AI Floods Financial Advice, a 60-Year Columbus Firm Doubles Down on What Cannot Be Automated: JudgmentBriton Pictured Beside Burning Gaza School Faces Call for War Crimes InquiryMercury Launches Next-Generation Retail Automation Platform to Expand 24/7 Retail Access Across Airports, Hospitality and High-Demand Locations
News

Calyxha Biotechnologies Announces Grant of a European Patent on Neurodegenerative Diseases

Richard Powell  2 min read
Illustration: greatreporter

Austrian biotech company Calyxha Biotechnologies GmbH is pleased to announce the grant of European Patent No. EP3383381. This patent covers the use of calixarene compounds for neurodegenerative diseases, including Parkinson’s disease. It represents the company’s first granted patent, with prosecution of the corresponding patent applications ongoing in other territories.

“Calyxha’s approach to drug development is to pursue drugs with novel mechanisms of action that address pathways involved in tissue degeneration. Therapeutic use of calixarenes represents a unique approach to neurodegenerative diseases such as Parkinson’s disease” said Dr Eszter Nagy, MD PhD, CEO and co-founder of Calyxha Biotechnologies GmbH. "The combination of innovative science and strong IP protection supports Calyxha to attract further investments to expand our opportunities in building a pipeline of new drugs," concluded Dr. Nagy.

“It is exciting to see our original research developing within Calyxha" commented Professor Robert Konrat, CSO and co-founder of Calyxha.  "This patent grant moves us closer to accomplishing our goal of developing a drug for neurodegenerative diseases based on novel mechanisms uncovered by our research”.

This patent is part of a series of patent applications resulting from original research by Professor Konrat and his group, and is exclusively licensed by Calyxha from the University of Vienna. “We are pleased to see this first patent grant for Calyxha, an excellent example of how basic research can be turned into promising product candidates for the benefit of people suffering from Parkinson’s” said Ronald Maier, Vice Rector for Digitalisation and Knowledge Transfer at the University of Vienna. “We wish this cooperation to successfully continue their development programme."

Calyxha is currently a preclinical stage company, developing novel therapies targeting tissue degeneration that is the fundamental underlying cause of major human diseases.

Calyxha Biotechnologies GmbH (http://www.calyxha.com/) is an Austrian biotech company founded in 2019 by Eszter Nagy MD PhD, Founder and CEO of CEBINA GmbH (Central European Biotech Incubator and Accelerator), Co-founder and President of Eveliqure Biotechnologies GmbH, previously Co-founder and CSO of Arsanis Inc, Vice President and Global Head of Research at Intercell AG (now Valneva SAS); Prof Robert Konrat, PhD (University of Vienna, Max F. Perutz Laboratories) and scientists Marco Sealey, PhD and Tanja Gesell, PhD, Wolfgang Friedl and CEBINA. Calyxha is located on the Vienna Biocenter Campus, and incubated and accelerated by CEBINA (www.cebina.eu). Calyxha is a product development company in the pre-clinical stage and also applies its drug discovery technology in industry partnerships.

Related articles

Top